|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000073282 |
Summary for TP63 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000073282 | Gene symbol | TP63 |
| Gene name | tumor protein p63 | |
| HGNC | 15979 | |
| Entrez ID | 8626 | |
| Gene type | protein_coding | |
| Synonyms | TP63|p51|SHFM4|EEC3|p63|p73L|OFC8|KET|p73H|NBP|p53CP|p40 | |
| UniProtAcc | Q9H3D4 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for TP63 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| TP63 | 8.91e+02 | -2.87e+00 | 5.43e-01 | -5.28e+00 | 1.27e-07 | 1.23e-05 | BRCA |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| TP63 | 2.80e+04 | 1.03e+00 | 1.75e-01 | 5.87e+00 | 4.44e-09 | 2.36e-08 | HNSC |
| TP63 | 6.77e+03 | 1.26e+00 | 5.42e-01 | 2.32e+00 | 2.03e-02 | 4.35e-02 | BLCA |
| TP63 | 1.16e+02 | 1.24e+00 | 3.90e-01 | 3.18e+00 | 1.47e-03 | 3.95e-03 | STAD |
| TP63 | 3.05e+04 | 3.78e+00 | 9.58e-01 | 3.94e+00 | 8.03e-05 | 8.43e-04 | ESCA |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| TP63 | 2.51e+01 | -1.44e+00 | 5.93e-01 | -2.42e+00 | 1.55e-02 | 4.52e-02 | KIRP |
| TP63 | 1.31e+03 | -2.58e+00 | 1.81e-01 | -1.43e+01 | 3.80e-46 | 3.39e-45 | BRCA |
Top |
Sex-biased somatic mutation for TP63 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for TP63 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| ACC | cg04489243 | chr3:189631340 | CGI:chr3:190120291-190121090 | promoter | 6.93e-01 | 5.59e-01 | 2.40e+00 | 1.64e-02 | 3.26e-02 | 1.34e-01 |
| ACC | cg05129081 | chr3:189631147 | CGI:chr3:190120291-190121090 | promoter | 4.59e-01 | 2.69e-01 | 3.12e+00 | 1.79e-03 | 8.40e-03 | 1.90e-01 |
| CHOL | cg16764781 | chr3:189630031 | CGI:chr3:190120291-190121090 | promoter | 5.20e-01 | 3.71e-01 | 2.29e+00 | 2.19e-02 | 3.45e-02 | 1.49e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUAD | cg04489243 | chr3:189631340 | CGI:chr3:190120291-190121090 | promoter | 7.24e-01 | 8.79e-01 | -3.05e+00 | 2.26e-03 | 3.85e-03 | -1.56e-01 |
| LUSC | cg16764781 | chr3:189630031 | CGI:chr3:190120291-190121090 | promoter | 5.95e-01 | 3.88e-01 | 2.36e+00 | 1.81e-02 | 2.20e-02 | 2.06e-01 |
| LUSC | cg12188416 | chr3:189631214 | CGI:chr3:190120291-190121090 | promoter | 5.62e-01 | 4.03e-01 | 2.52e+00 | 1.17e-02 | 1.57e-02 | 1.59e-01 |
| LUSC | cg06720722 | chr3:189631232 | CGI:chr3:190120291-190121090 | promoter | 6.28e-01 | 4.86e-01 | 2.03e+00 | 4.23e-02 | 4.36e-02 | 1.41e-01 |
| COAD | cg16764781 | chr3:189630031 | CGI:chr3:190120291-190121090 | promoter | 4.60e-01 | 7.61e-01 | -2.47e+00 | 1.36e-02 | 1.83e-02 | -3.01e-01 |
| COAD | cg04489243 | chr3:189631340 | CGI:chr3:190120291-190121090 | promoter | 6.83e-01 | 8.93e-01 | -2.36e+00 | 1.83e-02 | 2.31e-02 | -2.10e-01 |
| BLCA | cg21723486 | chr3:189631534 | CGI:chr3:190120291-190121090 | promoter,exon,CDS,gene body | 6.50e-01 | 8.68e-01 | -2.97e+00 | 2.97e-03 | 5.37e-03 | -2.18e-01 |
| LIHC | cg05129081 | chr3:189631147 | CGI:chr3:190120291-190121090 | promoter | 2.25e-01 | 3.30e-01 | -4.76e+00 | 1.96e-06 | 6.64e-06 | -1.04e-01 |
| KIRP | cg06720722 | chr3:189631232 | CGI:chr3:190120291-190121090 | promoter | 8.30e-01 | 6.72e-01 | 5.12e+00 | 3.06e-07 | 2.07e-06 | 1.57e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| HNSC | cg12188416 | chr3:189631214 | CGI:chr3:190120291-190121090 | promoter | 6.85e-01 | 5.59e-01 | 2.51e+00 | 1.20e-02 | 2.06e-02 | 1.26e-01 |
| BLCA | cg16764781 | chr3:189630031 | CGI:chr3:190120291-190121090 | promoter | 6.28e-01 | 4.86e-01 | 2.76e+00 | 5.70e-03 | 1.23e-02 | 1.42e-01 |
| LIHC | cg04483101 | chr3:189631489 | CGI:chr3:190120291-190121090 | UTR,promoter,exon,gene body | 8.23e-01 | 9.33e-01 | -3.76e+00 | 1.71e-04 | 5.79e-04 | -1.10e-01 |
Top |
Exon skipping events with PSI in TCGA for TP63 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for TP63 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for TP63 |
| TFs related to TP63. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| GBM | ARGFX | TP63 | 5.01e+00 | 9.83e-01 | 4.02e+00 | 1.40e-02 | Male-biased |
| GBM | FOXD2 | TP63 | 4.40e+00 | 9.85e-01 | 3.21e+00 | 7.26e-03 | Male-biased |
| GBM | FOXR2 | TP63 | 4.07e+00 | 9.82e-01 | 2.58e+00 | 2.74e-03 | Male-biased |
| GBM | ISX | TP63 | 4.89e+00 | 9.80e-01 | 3.94e+00 | 1.63e-02 | Male-biased |
| GBM | LMX1B | TP63 | 4.29e+00 | 9.84e-01 | 3.05e+00 | 6.20e-03 | Male-biased |
| GBM | ZNF300 | TP63 | 1.49e+00 | 1.38e-04 | 3.97e+00 | 9.84e-01 | Female-biased |
| GBM | ZNF333 | TP63 | 2.16e+00 | 7.70e-04 | 4.16e+00 | 9.89e-01 | Female-biased |
| GBM | ZNF343 | TP63 | 2.59e+00 | 3.29e-03 | 4.07e+00 | 9.84e-01 | Female-biased |
| GBM | ZNF37A | TP63 | 1.69e+00 | 4.40e-04 | 3.87e+00 | 9.80e-01 | Female-biased |
| GBM | ZNF415 | TP63 | 1.66e+00 | 2.60e-04 | 3.98e+00 | 9.84e-01 | Female-biased |
| GBM | ZNF418 | TP63 | 3.96e+00 | 9.80e-01 | 1.64e+00 | 1.29e-04 | Male-biased |
| GBM | ZNF431 | TP63 | 2.17e+00 | 1.27e-03 | 4.00e+00 | 9.84e-01 | Female-biased |
| GBM | ZNF552 | TP63 | 3.07e+00 | 5.59e-03 | 4.35e+00 | 9.87e-01 | Female-biased |
| GBM | ZNF554 | TP63 | 1.71e+00 | 4.22e-04 | 3.90e+00 | 9.81e-01 | Female-biased |
| GBM | ZNF563 | TP63 | 2.02e+00 | 5.53e-04 | 4.13e+00 | 9.88e-01 | Female-biased |
| GBM | ZNF616 | TP63 | 2.38e+00 | 2.22e-03 | 4.00e+00 | 9.83e-01 | Female-biased |
| GBM | ZNF641 | TP63 | 2.86e+00 | 5.18e-03 | 4.16e+00 | 9.84e-01 | Female-biased |
| GBM | ZNF662 | TP63 | 1.76e+00 | 3.95e-04 | 3.97e+00 | 9.84e-01 | Female-biased |
| GBM | ZNF740 | TP63 | 1.41e+00 | 1.37e-04 | 3.89e+00 | 9.81e-01 | Female-biased |
| GBM | ZNF79 | TP63 | 4.07e+00 | 9.83e-01 | 2.48e+00 | 1.97e-03 | Male-biased |
| LAML | ARGFX | TP63 | 3.63e+00 | 5.02e-04 | 5.28e+00 | 9.97e-01 | Female-biased |
| LAML | ELF3 | TP63 | 2.30e+00 | 2.35e-04 | 4.10e+00 | 9.84e-01 | Female-biased |
| LAML | FOXD2 | TP63 | 2.84e+00 | 3.25e-04 | 4.58e+00 | 9.92e-01 | Female-biased |
| LAML | FOXL1 | TP63 | 1.96e+00 | 4.18e-05 | 4.13e+00 | 9.85e-01 | Female-biased |
| LAML | FOXR2 | TP63 | 1.94e+00 | 1.47e-05 | 4.33e+00 | 9.89e-01 | Female-biased |
| LAML | HOXB7 | TP63 | 3.47e+00 | 8.06e-04 | 5.01e+00 | 9.95e-01 | Female-biased |
| LAML | HOXB8 | TP63 | 3.76e+00 | 1.32e-03 | 5.18e+00 | 9.96e-01 | Female-biased |
| LAML | HOXB9 | TP63 | 5.41e+00 | 3.81e-03 | 6.57e+00 | 9.96e-01 | Female-biased |
| LAML | IRF8 | TP63 | 3.94e+00 | 1.07e-02 | 4.82e+00 | 9.84e-01 | Female-biased |
| LAML | ISX | TP63 | 3.53e+00 | 6.04e-04 | 5.14e+00 | 9.96e-01 | Female-biased |
| LAML | LMX1B | TP63 | 2.51e+00 | 1.45e-04 | 4.42e+00 | 9.90e-01 | Female-biased |
| LAML | NKX2-2 | TP63 | 3.17e+00 | 5.42e-04 | 4.80e+00 | 9.94e-01 | Female-biased |
| LAML | NKX6-1 | TP63 | 2.15e+00 | 4.43e-05 | 4.31e+00 | 9.89e-01 | Female-biased |
| LAML | PBX2 | TP63 | 3.44e+00 | 1.42e-03 | 4.84e+00 | 9.94e-01 | Female-biased |
| LAML | POU3F1 | TP63 | 4.23e+00 | 1.79e-03 | 5.58e+00 | 9.97e-01 | Female-biased |
| LAML | POU3F4 | TP63 | 4.42e+00 | 2.02e-03 | 5.74e+00 | 9.97e-01 | Female-biased |
| LAML | POU6F1 | TP63 | 3.99e+00 | 1.25e-03 | 5.42e+00 | 9.97e-01 | Female-biased |
| LAML | SOX5 | TP63 | 3.72e+00 | 9.92e-04 | 5.21e+00 | 9.96e-01 | Female-biased |
| LAML | ZNF317 | TP63 | 3.31e+00 | 2.29e-03 | 4.59e+00 | 9.90e-01 | Female-biased |
| LAML | ZNF333 | TP63 | 4.02e+00 | 9.82e-01 | 2.04e+00 | 1.13e-04 | Male-biased |
| LAML | ZNF418 | TP63 | 1.08e+00 | 9.70e-07 | 4.15e+00 | 9.86e-01 | Female-biased |
| LAML | ZNF431 | TP63 | 4.14e+00 | 9.85e-01 | 2.10e+00 | 8.73e-05 | Male-biased |
| LAML | ZNF552 | TP63 | 4.22e+00 | 9.82e-01 | 3.10e+00 | 4.63e-03 | Male-biased |
| LAML | ZNF584 | TP63 | 2.53e+00 | 1.55e-04 | 4.43e+00 | 9.91e-01 | Female-biased |
| LAML | ZNF616 | TP63 | 4.02e+00 | 9.81e-01 | 2.48e+00 | 8.30e-04 | Male-biased |
| LAML | ZNF716 | TP63 | 2.55e+00 | 5.41e-04 | 4.17e+00 | 9.86e-01 | Female-biased |
| LAML | ZNF79 | TP63 | 1.79e+00 | 1.69e-05 | 4.14e+00 | 9.85e-01 | Female-biased |
| PAAD | FOXD2 | TP63 | 4.09e+00 | 9.83e-01 | 3.09e+00 | 4.19e-03 | Male-biased |
| PAAD | ISX | TP63 | 4.58e+00 | 9.83e-01 | 3.77e+00 | 1.10e-02 | Male-biased |
| PAAD | LMX1B | TP63 | 3.92e+00 | 9.82e-01 | 2.71e+00 | 1.40e-03 | Male-biased |
| PAAD | SOX5 | TP63 | 4.70e+00 | 9.86e-01 | 3.86e+00 | 9.43e-03 | Male-biased |
| PAAD | ZNF333 | TP63 | 2.55e+00 | 8.32e-04 | 3.82e+00 | 9.81e-01 | Female-biased |
| PAAD | ZNF616 | TP63 | 2.81e+00 | 1.42e-03 | 3.99e+00 | 9.85e-01 | Female-biased |
| PAAD | ZNF662 | TP63 | 2.40e+00 | 2.02e-04 | 3.93e+00 | 9.85e-01 | Female-biased |
| PAAD | ZNF740 | TP63 | 2.43e+00 | 4.18e-04 | 3.83e+00 | 9.82e-01 | Female-biased |
| UVM | FOXL1 | TP63 | 3.76e+00 | 1.12e-02 | 5.00e+00 | 9.82e-01 | Female-biased |
| UVM | FOXR2 | TP63 | 3.82e+00 | 1.15e-02 | 5.05e+00 | 9.82e-01 | Female-biased |
| UVM | NKX6-1 | TP63 | 3.80e+00 | 1.18e-02 | 5.01e+00 | 9.81e-01 | Female-biased |
| UVM | ZNF418 | TP63 | 3.78e+00 | 3.56e-03 | 5.60e+00 | 9.94e-01 | Female-biased |
| UVM | ZNF79 | TP63 | 3.71e+00 | 7.13e-03 | 5.19e+00 | 9.88e-01 | Female-biased |
| UVM | ZNF879 | TP63 | 3.45e+00 | 7.05e-03 | 4.92e+00 | 9.85e-01 | Female-biased |
| TP63 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
 |
Top |
Sex-biased RBP-ES network for TP63 |
| RBPs related to ES in TP63. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| TP63 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000073282 | AC022364.1,hsa-mir-203a,TP63 | Male-specific ceRNA | TCGA-BLCA |
| ENSG00000073282 | AC100861.1,hsa-mir-203a,TP63 | Male-specific ceRNA | TCGA-BLCA |
| ENSG00000073282 | SNHG4,hsa-mir-32,TP63 | Male-specific ceRNA | TCGA-BLCA |
| ENSG00000073282 | AL049555.1,hsa-mir-32,TP63 | Male-specific ceRNA | TCGA-BLCA |
| ENSG00000073282 | AC022364.1,hsa-mir-340,TP63 | Male-specific ceRNA | TCGA-BLCA |
| ENSG00000073282 | AC078883.1,hsa-mir-340,TP63 | Male-specific ceRNA | TCGA-BLCA |
| ENSG00000073282 | DARS-AS1,hsa-mir-372,TP63 | Male-specific ceRNA | TCGA-BLCA |
| ENSG00000073282 | AC099487.1,hsa-mir-372,TP63 | Male-specific ceRNA | TCGA-BLCA |
| ENSG00000073282 | AP001432.1,hsa-mir-493,TP63 | Male-specific ceRNA | TCGA-HNSC |
| ENSG00000073282 | AC005165.1,hsa-mir-204,TP63 | Male-specific ceRNA | TCGA-LIHC |
| ENSG00000073282 | AC005165.1,hsa-mir-211,TP63 | Male-specific ceRNA | TCGA-LIHC |
| ENSG00000073282 | AL136982.6,hsa-mir-373,TP63 | Male-specific ceRNA | TCGA-STAD |
| ENSG00000073282 | LINC01395,hsa-mir-373,TP63 | Male-specific ceRNA | TCGA-STAD |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs2630247 | chr3:193926950:A:G | - | -0.059066537857265 | 0.0066531127092389 | LUAD | Female-baised eQTL |
| rs2636914 | chr3:193935748:T:C | - | -0.0465427536395729 | 0.0142036263163607 | LUAD | Female-baised eQTL |
| rs2636910 | chr3:193937841:C:T | - | -0.0464545471854569 | 0.0147893750233659 | LUAD | Female-baised eQTL |
| rs4687470 | chr3:193933511:T:C | - | -0.046153182593124 | 0.0165952952093697 | LUAD | Female-baised eQTL |
| rs57448281 | chr3:191192103:G:T | - | 0.0730876029913756 | 0.0194055620330699 | LUAD | Female-baised eQTL |
| rs55866170 | chr3:191193112:C:T | - | 0.0671238667573893 | 0.0321762844678839 | LUAD | Female-baised eQTL |
| rs7651313 | chr3:193928283:T:G | - | -0.0474726459246186 | 0.0408317569622199 | LUAD | Female-baised eQTL |
| rs2636906 | chr3:193924816:A:G | - | -0.0472836406083042 | 0.0426441271777943 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs176820 | chr3:191376870:A:C | - | 0.0528482528323666 | 0.0113791196577373 | BLCA | Male-baised eQTL |
| rs367747 | chr3:191377834:A:G | - | 0.0512905933540828 | 0.0131879749472916 | BLCA | Male-baised eQTL |
| rs697905 | chr3:191369762:G:A | - | 0.0506167519749645 | 0.016121618268541 | BLCA | Male-baised eQTL |
| rs293805 | chr3:191373570:G:A | - | 0.0506167519749645 | 0.016121618268541 | BLCA | Male-baised eQTL |
| rs293802 | chr3:191363417:G:T | - | 0.0482743926137313 | 0.0315117622704755 | BLCA | Male-baised eQTL |
| rs293800 | chr3:191365046:C:A | - | 0.0481117754188364 | 0.0326533958518765 | BLCA | Male-baised eQTL |
| rs293806 | chr3:191375645:A:G | - | 0.0467900180495524 | 0.0369586286209576 | BLCA | Male-baised eQTL |
| rs426466 | chr3:191411826:G:C | - | -0.0457242324484956 | 0.0498629294151622 | BLCA | Male-baised eQTL |
| rs28459095 | chr3:197207120:G:C | - | -0.068578227852955 | 0.00060188165974334 | LUAD | Male-baised eQTL |
| rs670252 | chr3:193832823:A:G | - | -0.0705494153846444 | 0.000656562741124287 | LUAD | Male-baised eQTL |
| rs1839741 | chr3:197146830:A:G | - | -0.0634275364248533 | 0.00161476919012513 | LUAD | Male-baised eQTL |
| rs75489423 | chr3:183546252:C:T | - | 0.0644339913670141 | 0.00242585639693722 | LUAD | Male-baised eQTL |
| rs115077394 | chr3:186907538:T:G | - | 0.0520539518209725 | 0.00259533225949591 | LUAD | Male-baised eQTL |
| rs7631413 | chr3:194799988:G:T | - | 0.0601118950558324 | 0.00309782737891881 | LUAD | Male-baised eQTL |
| rs58369408 | chr3:183542285:C:T | - | 0.0627008119491602 | 0.00330088026408725 | LUAD | Male-baised eQTL |
| rs62292548 | chr3:186904045:T:G | - | 0.0510129335010679 | 0.00338586584377053 | LUAD | Male-baised eQTL |
| rs62294586 | chr3:186907279:C:G | - | 0.0510129335010679 | 0.00338586584377053 | LUAD | Male-baised eQTL |
| rs35923019 | chr3:186933599:C:T | - | 0.0504133140360716 | 0.0037519759936402 | LUAD | Male-baised eQTL |
| rs2687735 | chr3:193840293:G:A | - | -0.0599383854762491 | 0.00398403691795224 | LUAD | Male-baised eQTL |
| rs35376159 | chr3:186931140:T:A | - | 0.0493062718941618 | 0.00491511272044669 | LUAD | Male-baised eQTL |
| rs35461422 | chr3:186931889:A:G | - | 0.0493062718941618 | 0.00491511272044669 | LUAD | Male-baised eQTL |
| rs35102841 | chr3:186931894:A:G | - | 0.0493062718941618 | 0.00491511272044669 | LUAD | Male-baised eQTL |
| rs57950484 | chr3:183542601:C:T | - | 0.0606434151767022 | 0.00502854869277436 | LUAD | Male-baised eQTL |
| rs11914887 | chr3:183542731:A:G | - | 0.0606434151767022 | 0.00502854869277436 | LUAD | Male-baised eQTL |
| rs11922733 | chr3:183542971:C:T | - | 0.0606434151767022 | 0.00502854869277436 | LUAD | Male-baised eQTL |
| rs73884515 | chr3:183544280:A:C | - | 0.0606434151767022 | 0.00502854869277436 | LUAD | Male-baised eQTL |
| rs73884516 | chr3:183544313:T:C | - | 0.0606434151767022 | 0.00502854869277436 | LUAD | Male-baised eQTL |
| rs73884517 | chr3:183544471:G:A | - | 0.0606434151767022 | 0.00502854869277436 | LUAD | Male-baised eQTL |
| rs10937275 | chr3:186933001:A:G | - | -0.0492530617082836 | 0.00506405872229315 | LUAD | Male-baised eQTL |
| rs62294593 | chr3:186924322:T:G | - | 0.0488182613589585 | 0.0053174370472148 | LUAD | Male-baised eQTL |
| rs79473458 | chr3:187041400:G:A | - | 0.0578253064384413 | 0.00568370196443661 | LUAD | Male-baised eQTL |
| rs536570 | chr3:185538108:A:G | - | -0.0665639798581867 | 0.00598987884605149 | LUAD | Male-baised eQTL |
| rs13059833 | chr3:186929028:G:T | - | 0.0484150343752583 | 0.00611018475973957 | LUAD | Male-baised eQTL |
| rs3773844 | chr3:197086173:C:A | - | -0.0525299288220832 | 0.00811864949706675 | LUAD | Male-baised eQTL |
| rs13096543 | chr3:185399541:A:G | - | -0.0553530562509263 | 0.00836408705854103 | LUAD | Male-baised eQTL |
| rs12632135 | chr3:190578630:G:A | - | 0.0580869999879697 | 0.00870997262152403 | LUAD | Male-baised eQTL |
| rs34695488 | chr3:186926674:A:G | - | 0.0462851275805718 | 0.00938383996358115 | LUAD | Male-baised eQTL |
| rs58111844 | chr3:197472832:C:T | - | 0.0578122464628704 | 0.0097313132700939 | LUAD | Male-baised eQTL |
| rs9861933 | chr3:192210914:G:C | - | 0.0525930925100781 | 0.0102136696939629 | LUAD | Male-baised eQTL |
| rs35166820 | chr3:186928351:C:T | - | 0.0455057276222319 | 0.0110082645527261 | LUAD | Male-baised eQTL |
| rs59430654 | chr3:183547501:G:C | - | 0.0551168508279928 | 0.0140214856694561 | LUAD | Male-baised eQTL |
| rs1697346 | chr3:193839466:A:G | - | -0.0481126890562315 | 0.0159717392691153 | LUAD | Male-baised eQTL |
| rs522124 | chr3:193842710:A:G | - | -0.0468096088675212 | 0.0193273913705304 | LUAD | Male-baised eQTL |
| rs534571 | chr3:193839911:A:G | - | -0.0450971818322154 | 0.0334504586476902 | LUAD | Male-baised eQTL |
| rs181527426 | chr3:183957810:A:G | - | 0.0427670144515319 | 0.0400164925675243 | LUAD | Male-baised eQTL |
| rs7617545 | chr3:196626685:C:T | - | 0.0522627484833118 | 0.0411100497254532 | LUAD | Male-baised eQTL |
| rs59602417 | chr3:187206093:G:T | - | 0.0551087197065015 | 0.0411142083577 | LUAD | Male-baised eQTL |
| rs9865974 | chr3:187208326:A:T | - | 0.0551087197065015 | 0.0411142083577 | LUAD | Male-baised eQTL |
| rs113619747 | chr3:183957175:C:T | - | 0.0420202332451287 | 0.0455966831154033 | LUAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000073282 |
| CpG Site: cg18304052 | |
| Position to Gene: gene,exon,UTR | |
| Male Effect: - | |
| Female Effect: -0.273188902485429 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg18304052 | chr3:189896747 | gene,exon,UTR | -0.273188902485429 | 3.99288400515888e-05 | -0.3129501916190112 | 4.3991986645239863e-07 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of TP63 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000073282 | TP63 | C0000772 | Multiple congenital anomalies | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0001418 | Adenocarcinoma | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0006145 | Breast Diseases | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0007097 | Carcinoma | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0007137 | Squamous cell carcinoma | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0007621 | Neoplastic Cell Transformation | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0008924 | Cleft upper lip | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0008925 | Cleft Palate | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0009402 | Colorectal Carcinoma | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0009404 | Colorectal Neoplasms | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0016508 | Congenital Foot Deformity | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0018566 | Congenital Hand Deformities | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0024121 | Lung Neoplasms | 2 | CTD_human |
| ENSG00000073282 | TP63 | C0027627 | Neoplasm Metastasis | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0030297 | Pancreatic Neoplasm | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0037268 | Skin Abnormalities | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0038987 | Sweat Gland Neoplasms | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0152013 | Adenocarcinoma of lung (disorder) | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0205641 | Adenocarcinoma, Basal Cell | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0205642 | Adenocarcinoma, Oxyphilic | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0205643 | Carcinoma, Cribriform | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0205644 | Carcinoma, Granular Cell | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0205645 | Adenocarcinoma, Tubular | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0205696 | Anaplastic carcinoma | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0205697 | Carcinoma, Spindle-Cell | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0205698 | Undifferentiated carcinoma | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0205699 | Carcinomatosis | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0206720 | Squamous Cell Neoplasms | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0206762 | Limb Deformities, Congenital | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0242379 | Malignant neoplasm of lung | 2 | CTD_human |
| ENSG00000073282 | TP63 | C0346647 | Malignant neoplasm of pancreas | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0376634 | Craniofacial Abnormalities | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0406704 | Rudiger syndrome 1 | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0406709 | Hay-Wells syndrome | 2 | CTD_human |
| ENSG00000073282 | TP63 | C0751688 | Malignant Squamous Cell Neoplasm | 1 | CTD_human |
| ENSG00000073282 | TP63 | C0919267 | ovarian neoplasm | 1 | CTD_human |
| ENSG00000073282 | TP63 | C1140680 | Malignant neoplasm of ovary | 1 | CTD_human |
| ENSG00000073282 | TP63 | C1449718 | Endocrine Breast Diseases | 1 | CTD_human |
| ENSG00000073282 | TP63 | C1720887 | Female Urogenital Diseases | 1 | CTD_human |
| ENSG00000073282 | TP63 | C1785148 | RAPP-HODGKIN SYNDROME | 3 | CTD_human |
| ENSG00000073282 | TP63 | C1837218 | Cleft palate, isolated | 1 | CTD_human |
| ENSG00000073282 | TP63 | C1854442 | SPLIT-HAND/FOOT MALFORMATION 4 | 1 | CTD_human |
| ENSG00000073282 | TP63 | C1858562 | ECTRODACTYLY, ECTODERMAL DYSPLASIA, AND CLEFT LIP/PALATE SYNDROME 3 | 1 | CTD_human |
| ENSG00000073282 | TP63 | C1863204 | ADULT SYNDROME | 1 | CTD_human |
| ENSG00000073282 | TP63 | C1863753 | LIMB-MAMMARY SYNDROME | 1 | CTD_human |
